BioVentrix Is Treating Hearts Post-Attack

BioVentrix Is Treating Hearts Post-Attack

MPO's Sean Fenske speaks with Ken Miller of BioVentrix about how his LIVE Therapy system is helping heart attack victims recover.

By Sean Fenske, Editor-in-Chief03.09.21
In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Ken Miller, CEO of BioVentrix. He shares insights on how his technology helps to treat patients who have suffered from a heart attack and aren’t responding well to the traditional stent protocol. His solution helps bring the heart back to its normal size after the attack to prevent heart failure from the enlarged heart getting tired. Specifically, the following questions are addressed.

  • Let’s start with an introduction to your company and its LIVE Therapy system. Can you tell us what that is and the treatment it offers?
  • The FDA granted your technology a breakthrough device designation. What was that application process like?
  • Have you seen a difference in how your submission is handled by the agency with the BDP designation compared to prior experience?
  • Your system is currently involved in a clinical trial. What have been the results of that thus far?
  • What is your anticipated timeline for the system to gain regulatory approval and see a market launch?

Listen to this episode and see what you think of the BioVentrix LIVE Therapy system. If you’d like to share thoughts, ask questions, or suggest a future participant for Medtech Matters, please reach out to me at sfenske@rodmanmedia.com.

Listen to the podcast streaming via the player or get the podcast on the Medtech Matters channel via your preferred vendor of podcasts, such as Apple Podcasts (iTunes) or Spotify.

Click here to review other podcasts.
Related Searches: